Format

Send to

Choose Destination
J Am Acad Dermatol. 2014 Dec;71(6):1144-50. doi: 10.1016/j.jaad.2014.09.012. Epub 2014 Oct 14.

Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.

Author information

1
Clinical Unit for Research Trials and Outcomes in Skin, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Alpert Medical School, Brown University, Providence, Rhode Island.
2
Alpert Medical School, Brown University, Providence, Rhode Island.
3
Clinical Unit for Research Trials and Outcomes in Skin, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
4
Clinical Unit for Research Trials and Outcomes in Skin, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: harvardskinstudies@partners.org.

Abstract

BACKGROUND:

Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin. Previous epidemiologic studies have been limited by small sample size.

OBJECTIVE:

We sought to describe the prevalence and comorbidities of HS in a large patient care database.

METHODS:

In this retrospective case-control study, we chart-validated all patients within a hospital database who received at least 1 billing code for HS between 1980 and 2013. Verified cases were matched with controls based on age, gender, and race. Prevalences of a priori selected comorbidities were compared between HS and control groups.

RESULTS:

A total of 2292 patients at Massachusetts General Hospital received at least 1 code for HS. A total of 1776 cases had a validated diagnosis of HS, yielding a prevalence of 0.08%. In unadjusted analysis, all comorbidities were diagnosed significantly more in HS compared with control including (in rank order of likelihood): smoking, arthropathies, dyslipidemia, polycystic ovarian syndrome, psychiatric disorders, obesity, drug dependence, hypertension, diabetes, thyroid disease, alcohol dependence, and lymphoma (all P < .01).

LIMITATIONS:

Control subjects were not validated for absence of HS and comorbidity validation was not performed for either group.

CONCLUSIONS:

Our results highlights the high comorbidity burden of patients with HS compared with matched control subjects.

KEYWORDS:

acne inversa; cardiovascular disease; comorbidities; hidradenitis; hidradenitis suppurativa; lymphoma; metabolic syndrome; obesity; prevalence

PMID:
25440440
DOI:
10.1016/j.jaad.2014.09.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center